China Biologic Products, Inc. Form 8-K November 08, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest event Reported): November 8, 2016

CHINA BIOLOGIC PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-34566 75-2308816

(State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization)

18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People's Republic of China (Address of Principal Executive Offices)

86-10-6598-3111

Registrant's telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

ITEM 8.01. OTHER EVENTS.

On November 8, 2016, Guizhou Taibang Biological Products Co. Ltd. ("Guizhou Taibang"), a wholly-owned subsidiary of China Biologic Products, Inc. (the "Company"), completed the capital withdrawal of its two former minority shareholders by paying the remaining balance of the consideration pursuant to an agreement dated July 31, 2016, a summary English translation of which was filed as an exhibit to the Company's current report on Form 8-K filed with the Securities and Exchange Commission on August 4, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 8, 2016 CHINA BIOLOGIC PRODUCTS, INC.

By: /s/ David (Xiaoying) Gao David (Xiaoying) Gao Chief Executive Officer